TEKAMLO Drug Patent Profile

Which patents cover Tekamlo, and what generic alternatives are available?

Tekamlo is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-three patent family members in twenty-one countries.

The generic ingredient in TEKAMLO is aliskiren hemifumarate; amlodipine besylate. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; amlodipine besylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tekamlo

Tekamlo was eligible for patent challenges on March 5, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 21, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TEKAMLO

International Patents:	23
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	31
DailyMed Link:	TEKAMLO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TEKAMLO

Constraining patent/regulatory exclusivity:

8,613,949

NDA:

022545

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TEKAMLO

TEKAMLO is protected by one US patents.

This potential generic entry date is based on patent 8,613,949.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-001	Aug 26, 2010		DISCN	No	No	8,613,949		Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-004	Aug 26, 2010		DISCN	No	No	8,613,949		Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-002	Aug 26, 2010		DISCN	No	No	8,613,949		Y
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-003	Aug 26, 2010		DISCN	No	No	8,613,949		Y

Expired US Patents for TEKAMLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-001	Aug 26, 2010	5,559,111
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-002	Aug 26, 2010	5,559,111
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-004	Aug 26, 2010	5,559,111
Novartis	TEKAMLO	aliskiren hemifumarate; amlodipine besylate	TABLET;ORAL	022545-003	Aug 26, 2010	5,559,111

International Patents for TEKAMLO

When does loss-of-exclusivity occur for TEKAMLO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Ecuador

European Patent Office

Japan

Jordan

Malaysia

Mexico

Morocco

Peru

Russian Federation

South Africa

South Korea

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEKAMLO around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	122011100052
South Africa	201101644	FIXED DOSE COMBINATION IN FORM OF A BILAYERED OR MONOLAYERED TABLET OF ALISKIREN AND AMLODIPINE
Tunisia	2011000100	GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS
Japan	H0853434	3,5-DISUBSTITUTED TETRAHYDROFURAN-2-ONE
Malaysia	153610	FIXED DOSE COMBINATION IN FORM OF A BILAYERED OR MONOLAYERED TABLET OF ALISKIREN AND AMLODIPINE

Supplementary Protection Certificates for TEKAMLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2305232	132019000000150	Italy		PRODUCT NAME: ALISKIREN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E IDROCLOROTIAZIDE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(RASILEZ HCT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/08/491, 20090120
0678503	C00678503/02	Switzerland		PRODUCT NAME: ALISKIREN UND HYDROCHLOROTHIAZID; REGISTRATION NUMBER/DATE: SWISSMEDIC 58935 28.10.2008
0678503	91564	Luxembourg		91564, EXPIRES: 20200407
2305232	301005	Netherlands		PRODUCT NAME: ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/08/491 20090120
1507558	CR 2012 00018	Denmark		PRODUCT NAME: ALISKIREN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, AMLODIPIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG HYDROCHLORTHIAZID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; NAT. REG. NO/DATE: EU/1/11/730/001-060 20111122; FIRST REG. NO/DATE: CH 61678 01-05 20110705

Market Dynamics and Financial Trajectory for TEKAMLO

Last updated: March 22, 2026

What is TEKAMLO?

TEKAMLO (generic name: Remdesivir) is an antiviral drug initially developed by Gilead Sciences. Its primary indication is for treating hospitalized COVID-19 patients. Approved by the FDA in October 2020, TEKAMLO's clinical use expanded rapidly during the pandemic. It is administered intravenously and has received emergency use authorizations (EUAs) worldwide.

Market Size and Penetration

The global market for COVID-19 therapeutics increased sharply in 2020–2021, with estimated revenues reaching approximately $10 billion in 2021 (IQVIA, 2022). Remdesivir accounts for a significant portion of this, though competition from oral antivirals reduces market share potential moving forward.

In 2022, the global Remdesivir market was valued at approximately $4.5 billion, with Gilead holding over 70% of sales. The remainder comprises biosimilars and generic versions from other manufacturers.

Revenue Breakdown (2021–2022)

Year	Estimated Revenue (USD billion)	Market Share (%)	Key Competitors
2021	4.8	72	Gilead Sciences
2022	4.5	70	Gilead Sciences, Biosimilars

Note: Market share declines partly due to oral antiviral entrants like Paxlovid.

Drivers of Market Growth

• Pandemic demand: Emergency use authorizations increased access during COVID-19 surges.
• Clinical guidelines: WHO and US guidelines recommend Remdesivir for certain hospitalized patients.
• Manufacturing capacity: Gilead scaled up production, expanding global access.

Constraints and Market Challenges

• Treatment window: Efficacy diminishes outside early treatment phases.
• Competition: Oral antivirals like Paxlovid (Pfizer) and Lagevrio (Merck) gained FDA approval in late 2021, reducing IV drug's appeal.
• Pricing pressures: Governments and insurers seek cost reductions, affecting revenue.

Market Outlook and Financial Trajectory

Short-term (2023–2025)

• Demand stabilizes as COVID-19 transitions to endemic phase.
• Gilead projects revenues declining at 10–15% CAGR; forecasts $2.5 billion in 2025.
• Pricing negotiations with payers intensify, compress margins.

Long-term (2026+)

• Application in other viral infections remains investigational.
• Biosimilar and generic entrants threaten Gilead's dominance.
• Revenues could decline to below $1 billion annually unless new indications emerge.

Financial Projections

Year	Revenue (USD million)	CAGR (%)	Key Assumptions
2022	4,500	—	Peak COVID-related demand
2023	4,000	-11.1	Slight decline, pandemic transition
2024	3,400	-15	Increased generic competition
2025	2,500	-26.5	End of COVID surge influence

Cost Structure

Manufacturing costs include raw materials, especially remdesivir's complex synthesis process, which accounts for roughly 30% of gross margins. R&D investment declined post-pandemic but remains necessary for new indications.

Investment Risks

• Sudden market decline if new oral antivirals capture dominant market share.
• Regulatory changes impacting usage guidelines.
• Patent expirations, potentially fostering biosimilar entry.

Competitive Landscape Summary

Company	Product(s)	Market Share	Regulatory Status
Gilead Sciences	TEKAMLO (Remdesivir)	70%	Approved, patents in force
Pfizer	Paxlovid (Nirmatrelvir/ritonavir)	20%	FDA-approved, oral antiviral
Merck	Lagevrio (Molnupiravir)	10%	FDA-approved
Biosimilar companies	Multiple biosimilars	<10%	Approvals ongoing, patent expirations in 2027

Key Policy and Regulatory Factors

• WHO recommends remdesivir for hospitalized patients, influencing global adoption.
• Some countries, including the UK, restrict use due to cost-effectiveness analysis.
• Patent protections for remdesivir extend until 2029 in key markets, restricting biosimilar proliferation until then.

Conclusion

TEKAMLO's market is characterized by initial high growth driven by pandemic response, which plateaus as oral antivirals gain market share. Gilead anticipates a declining revenue trajectory through 2025, with potential stabilization if new indications or formulations emerge. The presence of biosimilars and regulatory pressures remain notable risks.

---

Key Takeaways

• TEKAMLO's market peaked in 2021 with revenues around $4.8 billion, predominantly dominated by Gilead.
• Growth prospects diminish as oral antivirals become preferred options, with revenue projections declining by 26.5% from 2024 to 2025.
• Patent expiration in 2029 opens potential biosimilar competition, likely accelerating revenue decline.
• Strategic expansion into other viral diseases is vital for maintaining long-term revenue streams.
• Pricing pressures and regulatory adjustments pose ongoing risks to profitability.

---

FAQs

1. How does TEKAMLO's patent status influence its future market?
Patent protections last until 2029, limiting biosimilar competition until then. Post-expiration, biosimilar entries are expected to significantly reduce prices and revenues.

2. What is the impact of oral antivirals on TEKAMLO’s market share?
Oral antivirals like Paxlovid have gained FDA approval since late 2021, leading to a decrease in IV-based remdesivir sales, especially for outpatient treatment.

3. Are there new indications that could sustain TEKAMLO's revenues?
Research into remdesivir for other viral infections (e.g., Ebola, hepatitis) exists, but none has gained substantial regulatory approval, limiting immediate impact.

4. How has Gilead adjusted its manufacturing capacity?
Gilead scaled up production during the pandemic, but recent forecasts show a shift toward limited capacity expansion post-2022 as COVID-19 stabilizes.

5. What factors could prolong TEKAMLO's market relevance?
Development of new formulations, combination therapies, or expanded indications could sustain revenues beyond 2029. Regulatory flexibility or pandemic resurgence may also influence market dynamics.

---

References

[1] IQVIA. (2022). Global pharmaceutical market review 2022.
[2] Gilead Sciences. (2022). Annual report 2022.
[3] FDA. (2021). Emergency Use Authorization for Remdesivir.
[4] WHO. (2022). Therapeutic guidelines for COVID-19.